{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 40,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes trial schema (Part 1/2) and summary of patient characteristics, adverse events, and immune responses.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/23",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Trial design schema showing dose titration and expansion cohorts",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f2e7661-8df2-42fa-83fb-ac9ac29f1ce2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Patients: Stage 4, median age 68, 11 monotherapy, 3 combo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a99673ed-7a18-4f14-8e1e-6a59c4fa11ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.55
      },
      "kind": "list",
      "text": "Immune response: 7/7 evaluable patients, 5 antigens immunogenic, PSA decrease in 2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e71907cd-7e48-4216-b8c3-b1fc073f48e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.55
      },
      "kind": "list",
      "text": "AEs: mild-to-moderate, pyrexia/hypertension, no DLT, no safety signals",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f139aed0-9cd1-45df-814e-eb506c043c73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Data cutoff: 22 June 2021; mCRPC, metastatic castration-resistant prostate cancer; LPC, localized prostate cancer; REDR, recommended dose expansion range; AE, adverse event; DLT, dose-limiting toxicity; PSA, prostate-specific antigen",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60260ac7-f477-4e70-bc32-942a9bbd9802",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "BNT112 Phase 1/2: FixVac Off-the-Shelf mRNA Vaccine as Monotherapy and in Combination with PD-1 Inhibitor in Patients with Prostate Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af1f9ae5-0842-4878-808f-ea8462d65a24",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "86ee922b-3b38-407a-91d0-e5fba14e6389",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with financial results, outlook, and future plans",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8d1b4261-4f6e-4fae-a0eb-442f564dc509",
      "evidence": "The presentation mentions the potential to tackle multiple diseases with different therapeutic modalities",
      "position": 1,
      "objective": "To highlight the potential consequences of not addressing serious diseases",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}